Novavax

Global Vaccine Market Will Unlock Upside Despite Execution Risks

AnalystConsensusTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

22 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$13.14

27.6% undervalued

15 Aug

US$9.52

-26.9%

12.3%

Author's Valuation

US$13.1

27.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Decreased 2.13%

AnalystConsensusTarget Fair Value

US$13.1

27.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-31.47%

Biotech revenue growth rate

12.71%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.87%

Calculation

US$55.92m

Earnings '28

48.48x

PE Ratio '28

US$2.71b

Market Cap '28

US$2.71b

Market Cap '28

169.61m

No. shares '28

US$15.98

Share Price '28

US$15.98 Share Price '28

Discounted to 2025 @ 6.87% p.a.

US$13.10

Fair Value '25

Global Vaccine Market Will Unlock Upside Despite Execution Risks

Shared on01 May 25Fair value Decreased 2.13%

Shared on01 May 25
Fair value Decreased 2.13%